Literature DB >> 8512794

Deep vein thrombosis: the risks of sclerotherapy in hypercoagulable states.

C F Feied1.   

Abstract

There have been many case reports of deep vein thrombosis and pulmonary thromboembolism in patients undergoing sclerotherapy for the treatment of varicose veins, but the true incidence of venous thromboembolism in this patient population is unknown. Patients who develop deep vein thrombosis while being treated for varicose veins do so either because of an error in treatment or because the patient suffers from some underlying hypercoagulable state. It is possible to identify prospectively many patients who are at especially high risk for venous thromboembolism by virtue of genetic predisposition, past or recent medical problems, or environmental factors. When sclerotherapy is used in such patients, special efforts must be made to protect against the development of venous thrombosis during treatment.

Entities:  

Mesh:

Year:  1993        PMID: 8512794

Source DB:  PubMed          Journal:  Semin Dermatol        ISSN: 0278-145X


  4 in total

Review 1.  A guide to venous thromboembolism risk factor assessment.

Authors:  G D Motykie; L P Zebala; J A Caprini; C E Lee; J I Arcelus; J J Reyna; E B Cohen
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 2.  [Sclerotherapy for varicosities].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

3.  The possible risk of lower-limb sclerotherapy causing an extended hypercoagulable state.

Authors:  H Ariyoshi; J Kambayashi; S Tominaga; T Hatanaka
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Sclerotherapy for varicose veins of the lower legs in patients with dysplasminogenemia.

Authors:  M Ikeda; T Kawasaki; J Kambayashi; S Iwamoto; N Shinoki; T Nakamura; T Shibuya; M Monden
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.